Open-Label, Multicenter, Phase Ⅱ Study of Docetaxel and Cisplatin Combined With Nimotuzumab As First-Line Treatment in Patients With Recurrent or Metastatic Nasopharyngeal Carcinoma

Condition:   Over Survival
Intervention:   Drug: Docetaxel and Cisplatin and Nimotuzumab
Sponsor:   Sun Yat-sen University
Not yet recruiting

https://ift.tt/2yqWy9H